Q2 Solutions Q2 Solutions Actionable Insights for Better Health and Lab Solutions
Conference

11th Workshop on Recent Issues in
Bioanalysis (WRIB)

Visit Q2 Solutions at booth #3 and attend our presentations

Universal City, CA | April 03, 2017 - April 07, 2017 | 08:00 - 17:00 Add to Calendar
Stay Informed

About This Event

The 11th WRIB event is a forum where regulators and industry convene to work together in the field of bioanalysis, biomarkers, and immunogenicity to improve global health. Visit Q2 Solutions at this event to learn more about how we work with customers to solve some of today’s most challenging bioanalytical and ADME issues. Our scientific experts will be hosting speaking presentations as well as a poster presentation.

Panel Discussion Title: SM, Peptides, and SM Biomarkers by LCMS Panel Discussion & Consensus for 2017 White Paper in Bioanalysis
Date and Time: Monday, April 3, 2017 5:50-6:45pm
Panelist: Barry Jones
 
Training Course Title: Th-1 for LCMS Scientists: CRO latest Advanced Use of HRMS in fully GLP/Regulated Quantitative Bioanalysis (Lesson 5)
Date and Time:
Thursday, April 6, 2017 8:00am-5:30pm
Speaker:
Barry Jones

Poster Presentation Title
: Resolution of drug tolerance issues encountered with an Immunogenicity assay
Poster Presenter: Shoshana Oberstein
When: April 6, 2017 ; P01
 
We look forward to meeting you in Universal City, CA.

Register for Event

Speakers

Barry Jones, Ph.D.
Manager, LCMS Biologics and Biomarkers

Dr. Barry Jones joined Advion Biosciences in 2007, began the LCMS Biologics Group in 2008 under Dr. Gary Schultz, and now leads the large molecule LCMS method development group at Q2 Solutions.  Research within the LCMS biologics group at Q2 Solutions is focused on targeted quantitative LC-MS/MS analysis of endogenous biomolecules and large molecule biotherapeutics on triple quadrupole and orbitrap instruments. Dr. Jones is particularly interested in the application of hybrid Immunoaffinity-LC-MS/MS methods to high-throughput bioanalysis, as well as the scientific challenges and regulatory strategies for validation of LCMS biomarker assays supporting drug development in a regulated environment. 

Prior to joining Q2 Solutions, Dr. Jones led the Mass Spectrometry Facility at Binghamton University, N.Y. using Q-TOF and MALDI mass spectrometry and nanoESI techniques in support of proteomic research. He earned his Ph.D. in Physical Chemistry at Binghamton University in 2006.